"description","id","rationale","uuid:ID","name","instanceType","label"
"The main design for the study","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","d611401e-7348-4afa-aedb-6559ba9239f1","Study Design 1","StudyDesign",""
